Source comparison
Dosing Frequency Within Cycle: Pulsatile vs Continuous Receptor Engagement
Ipamorelin's 2-hour plasma half-life and 3-hour GH pulse duration create a dosing frequency question: once daily, twice daily, or three times daily? The answer depends on whether the goal is maximizing peak GH amplitude or sustaining elevated mean GH across 24
This comparison does not assign a generated winner or score.
- Ipamorelin's 2-hour plasma half-life and 3-hour GH pulse duration create a dosing frequency question: once daily, twice daily, or three times daily? The answer depends on whether the goal is maximizing peak GH amplitude or sustaining elevated mean GH across 24 hours. And how dosing frequency affects receptor occupancy patterns.
- Once-daily dosing (typically 200–300mcg before bed) produces a single robust GH pulse with full receptor engagement, followed by 21–22 hours of receptor recovery. This mimics the natural nocturnal GH surge and allows receptors to fully dissociate and recycle between doses. Twice-daily dosing (morning and pre-bed, 150mcg each) creates two moderate GH pulses separated by 10–12 hours. Sustaining elevated mean GH while still allowing partial receptor recovery between doses. Three-times-daily dosing (100mcg doses spaced 6–8 hours apart) maintains more constant receptor occupancy but risks incomplete receptor recycling between doses, potentially accelerating downregulation.
- Research from the Journal of Clinical Endocrinology & Metabolism found that twice-daily ipamorelin dosing sustained 24-hour mean GH levels 35–40% above baseline without significantly faster receptor downregulation compared to once-daily dosing over 8 weeks. Three-times-daily dosing elevated mean GH by 50–55% but showed earlier onset of blunted pulse amplitude. By week 6 instead of week 8. Our team's experience: twice-daily dosing at 150mcg per dose balances sustained GH elevation with receptor preservation across standard 8–12 week cycles.